Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04618263
Recruitment Status : Recruiting
First Posted : November 5, 2020
Last Update Posted : November 9, 2020
Sponsor:
Information provided by (Responsible Party):
Gate Neurosciences, Inc

Brief Summary:
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GATE-101 in normal human volunteers

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Excessive Sleepiness Drug: GATE-101 Phase 1

Detailed Description:

Single ascending dose (SAD), multiple ascending dose (MAD), double-blind placebo-controlled study in normal human volunteers.

Secondary objectives:

To evaluate the pharmacokinetics (PK) of GATE-101 following increasing single and multiple doses of intravenously (IV) administered GATE-101.

GATE-101 or Placebo: Dose/Mode of Administration: Single or 5 Daily Doses;Intravenous

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Triple, Participant, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Randomized Double-blind, Placebo-controlled Single and Multiple Intravenous Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of GATE-101 in Normal Healthy Volunteers
Actual Study Start Date : October 26, 2020
Estimated Primary Completion Date : April 1, 2021
Estimated Study Completion Date : June 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: GATE-101, 5 mg IV, Single Dose
GATE-101, 5 mg IV, Single Dose, with follow up of 28 days
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Experimental: GATE-101, 15 mg IV, Single Dose
GATE-101, 15 mg IV, Single Dose, with follow up of 28 days
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Experimental: GATE-101, 50 mg IV, Single Dose
GATE-101, 50 mg IV, Single Dose, with follow up of 28 days
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Experimental: GATE-101, 150 mg IV, Single Dose
GATE-101, 150 mg IV, Single Dose, with follow up of 28 days
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Experimental: GATE-101, 450 mg IV, Single Dose
GATE-101, 450 mg IV, Single Dose, with follow up of 28 days
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Experimental: GATE-101, 15 mg IV, Single Dose, Lumbar Catheter
GATE-101, 15 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Experimental: GATE-101, 50 mg IV, Single Dose, Lumbar Catheter
GATE-101, 50 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Experimental: GATE-101 5 mg IV, Five Daily Doses
GATE-101 5 mg IV, Five Daily Doses, with follow up for 28 days from first dose
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Experimental: GATE-101 15 mg IV, Five Daily Doses
GATE-101 15 mg IV, Five Daily Doses, with follow up for 28 days from first dose
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Experimental: GATE-101 150 mg IV, Five Daily Doses
GATE-101 150 mg IV, Five Daily Doses, with follow up for 28 days from first dose
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Placebo Comparator: Placebo Comparator, Single Dose
Placebo Comparator, Single Dose, with follow up for 28 days
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Placebo Comparator: Placebo Comparator, Five Daily Doses
Placebo Comparator, Five Daily Doses, with follow up for 28 days from first dose
Drug: GATE-101
GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist




Primary Outcome Measures :
  1. Number of Participants with Treatment-Emergent Adverse Events Through Study Completion, 28 days [ Time Frame: 28 Days ]
    Safety and Tolerabiity


Secondary Outcome Measures :
  1. Pharmacokinetics - maximum plasma concentration - following a single intravenous dose [ Time Frame: 72 hours ]
    Maximum observed plasma concentration following a single dose

  2. Pharmacokinetics - maximum plasma concentration - following 5 daily intravenous doses [ Time Frame: 72 hours ]
    Maximum observed plasma concentration following the fifth daily doses

  3. Pharmacokinetics - area under the curve - following a single intravenous dose [ Time Frame: 72 hours ]
    Area under the concentration time curve from time 0 to infinity following a single dose

  4. Pharmacokinetics - area under the curve - following 5 daily intravenous doses [ Time Frame: 72 hours ]
    Area under the concentration time curve from time 0 to infinity following the fifth daily dose



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Normal, healthy volunteer male and female subjects
  2. Aged 18 to 40 years
  3. For female subjects must meet one of the following:

    • Surgically sterile or at least 2 years menopausal, confirmed by follicle stimulating hormone (FSH) at screening visit, or,
    • If of childbearing potential, subject must use an acceptable method of birth control from date of screening to at least 30 days after the last dose of study drug. Must have a documented negative blood or urine pregnancy test within 24 hours prior to dosing. If reported sterile or postmenopausal, will be confirmed by FSH.
  4. For male subjects, must meet one of the following:

    • Surgically sterile
    • If not surgically sterile then use of an acceptable form of contraception (condom) from the time of randomization through 30 days following the last dose of study drug. Male subjects are strongly advised to inform female partners of the need for them to use highly effective birth control during this time period.
  5. Body mass index (BMI) < 30
  6. Clinical laboratory values <2 times the upper limit of normal (ULN) or deemed not clinically significant by the Investigator.
  7. Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.

Exclusion Criteria:

  1. Human immunodeficiency virus (HIV) infection, or hepatitis or other ongoing infectious disease
  2. Evidence of alcohol abuse (greater than 4 units of alcohol on most days; 1 unit = 1/2 pint of beer, 1 glass of wine or 1 oz. of spirits). Alcohol consumption should be avoided for at least 24 hours prior to baseline/dosing visit. A positive alcohol breathalyzer at screening and baseline visit
  3. Current abuse of illicit substances, using the Diagnostic and Statistical Manual (DSM) V definition of substance use disorder.
  4. Current cigarette/tobacco smoker or use of other tobacco or nicotine products including ecigarettes or vaping (if formerly a smoker must not have smoked for at least one year prior to enrolling in this study). Nonsmoking will be confirmed by cotinine assay.
  5. Currently pregnant, planning to become pregnant during the course of the study, or nursing mother
  6. Impaired renal function (GFR < 90 ml/min)
  7. Elevated systolic blood pressure (> 130 mmHg) or diastolic blood pressure (> 80 mmHg) and/or increased QTc (>450 msec for men or >470 msec for women) or additional risk factors for Torsades de Pointes including heart failure, hypokalemia, family history of Long QT Syndrome
  8. Type I or Type II diabetes
  9. Malignancy in the last 5 years, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  10. Currently taking prescription (except as listed in Section 7.4.1) or over-the-counter medications including herbal therapies, within 14 days of enrollment into the study.
  11. History of allergy or sensitivity, or intolerance to NMDAR ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone
  12. Received another investigational drug or device within 30 days of enrollment in this study
  13. Previously participated in this study
  14. Psychiatric disease including major depression, bipolar disorder, anxiety, or schizophrenia, or other medical condition that, in the opinion of the Investigator, would interfere with the evaluation of study drug safety
  15. For subjects in lumbar catheter Groups (6 and 7) has a history of excessive bleeding after invasive procedures or surgery or known coagulation or platelet abnormality, or has been on any blood thinner or medication affecting platelet function, such as aspirin, nonsteroidal anti-inflammatory medications, corticosteroids (except topical) or warfarin within the 7 days prior to enrollment, or has known allergy to any anesthetic agent that may be used for the lumbar puncture.
  16. For subjects in lumbar catheter Groups (6 and 7) has a history of infection that required IV antibiotics within the 45 days or oral antibiotics within 30 days prior to enrollment, and, at the time of clinic admission, be febrile or have signs/symptoms consistent with an infection.
  17. For subjects in lumbar catheter Groups (6 and 7) has a history of or physical examination evidence of a lumbar spine abnormality that may preclude placement of a spinal catheter, presence of intraspinal shunt devices (e.g. ventriculoperitoneal shunt), or history of elevated intracranial pressure, normal pressure hydrocephalus, or other neurological condition that in the opinion of the Investigator precludes safe study participation.
  18. In the opinion of the Investigator, the Safety Monitor, or the Sponsor Study Monitor, has a history of severe renal or hepatic impairment, severe active hepatic disease, or other clinically significant medical condition that may preclude safe study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04618263


Contacts
Layout table for location contacts
Contact: Magdy Shenouda, MD 212-994-4569 mshenouda@clinilabs.com

Locations
Layout table for location information
United States, New Jersey
Clinilabs Drug Development Corporation Recruiting
Eatontown, New Jersey, United States, 07724
Contact: Magdy Shenouda, MD    212-994-4569    mshenouda@clinilabs.com   
Sponsors and Collaborators
Gate Neurosciences, Inc
Investigators
Layout table for investigator information
Study Director: Ronald M Burch, MD, PhD Gate Neurosciences, Inc
Layout table for additonal information
Responsible Party: Gate Neurosciences, Inc
ClinicalTrials.gov Identifier: NCT04618263    
Other Study ID Numbers: GATE-101-C-101
First Posted: November 5, 2020    Key Record Dates
Last Update Posted: November 9, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gate Neurosciences, Inc:
Major Depressive Disorder
Excessive Sleepiness
Metabotropic Glutamate Type 2/3 Receptor Antagonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleepiness
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms